NeoAdjuvant Pembrolizumab and STEreotactic Radiotherapy Prior to Nephrectomy for Renal Cell Carcinoma
Status:
Not yet recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This is a prospective, open label, phase II, randomised, non-comparative clinical trial,
evaluating changes in tumour-responsive T-cells following neoadjuvant stereotactic ablative
body radiotherapy (SABR) with or without pembrolizumab, prior to nephrectomy, in patients
with localised primary clear cell renal cell carcinoma (ccRCC).